Annexon (ANNX) reported "rapid recovery and durable benefit" for patients in the phase 3 trial of tanruprubart, a potential targeted therapy for Guillain-Barre Syndrome,
The trial showed a 2.4-fold higher likelihood of improvement at week eight versus placebo in 241 patients, the company said Tuesday in a statement, with the results presented at the American Academy of Neurology annual meeting in San Diego.
Key findings showed that tanruprubart led to a 14-fold improvement in mobility at week one and twice as many patients had no limitations by week 26, the company said.
Shares of the company rose 3.3% in recent after-hours trading, paring earlier gains.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。